Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A tumor-cell MHC-II program is associated with checkpoint-blockade outcomes across stages of bladder cancer

Purpose A minority of patients with bladder cancer derive lasting benefit from immunotherapy, and current biomarkers capture only part of the biology. We evaluated whether tumor-cell MHC class II defines an immune state associated with outcome across disease stages and after PD-1/PD-L1 blockade. Experimental Design We...

J. Bellmunt, Ying-Tian Xie, M. Munoz et al. · 0 citations
Open access Jul 2026

Buildable linkers: Site-Specific Antibody-Drug Conjugates with Well-Defined Payloads 2308812

The benefits of creating a buildable drug scaffold that’s accommodating for achieving exact payload conjugated at a specific site on Trastuzumab are shown, which will enable all therapeutic antibodies to be conjugated in a uniform manner, accelerating the advancing field of ADC therapeutics.

Lisa Arvidson, Katarina Jovic-Dold, J. Halpern et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.